Search for: "AMGEN INC."
Results 581 - 600
of 707
Sorted by Relevance
|
Sort by Date
11 Jan 2012, 2:02 pm
" Amgen, Inc. v. [read post]
27 Aug 2012, 9:31 am
Relying on Amgen Inc. v. [read post]
20 Jan 2011, 2:20 pm
Amgen, Inc.: Section 502(a)(1)(B) allows a plan participant “to recover benefits due to him under the terms of his plan. [read post]
23 Oct 2008, 10:31 am
" Specifically, "infections triggered safety alerts for the arthritis medicines Enbrel (etanercept), sold by Amgen Inc.; Johnson & Johnson's Remicade (infliximab); and Abbott Laboratories' Humira (adalimumab). [read post]
27 Aug 2012, 9:31 am
Relying on Amgen Inc. v. [read post]
8 Dec 2009, 5:26 pm
" Amgen Inc. v. [read post]
8 Nov 2007, 11:56 pm
ALM Privacy Policy / Contact Us
© 2007 ALM Properties, Inc. [read post]
23 Aug 2023, 9:46 am
Steuben Foods, Inc. v. [read post]
13 Apr 2010, 10:26 am
See Amgen Inc. v. [read post]
22 Sep 2014, 4:23 am
Amerisource did not learn of the existence of the matter until March 2008, when Amgen informed Amerisource that Amgen was under investigation. [read post]
23 Apr 2014, 7:40 am
Amgen Inc. v. [read post]
21 Dec 2022, 11:57 am
Amgen, Inc., 2020 WL 9432700, at *5 (D. [read post]
3 Jul 2011, 11:08 pm
Flood, Inc. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
27 Aug 2012, 11:01 am
Relying on our decision in Amgen Inc. v. [read post]
17 Mar 2014, 5:13 pm
Teva Pharmaceuticals USA, Inc., 619 F.3d 1329 (Fed. [read post]
22 Jul 2024, 12:07 am
In the following I will focus on Decision CC_586764/2023 (UPC_14/2023), which is the counterclaim for revocation in the infringement action between Amgen Inc and Regeneron Pharmaceuticals Inc. that Amgen filed on the very first day when the UPC opened its doors (1 June 2023), a few minutes after Sanofi (Regeneron’s licensee) had filed a revocation action at the Central Division, which became the UPC’s very first case ever (UPC_1/2023). [read post]
12 May 2015, 3:30 pm
Inc. 90271J739 UBS Trigger Phoenix Autocallable Optimization Securities linked to Genworth Financial, Inc. 90271J721 UBS Trigger Phoenix Autocallable Optimization Securities linked to BlackRock, Inc. 90271J689 UBS Trigger Phoenix Autocallable Optimization Securities linked to Baidu, Inc. 90271J671 UBS Trigger Phoenix Autocallable Optimization Securities linked to Bank of America 90271J663 UBS Trigger Phoenix Autocallable Optimization Securities linked to U.S. [read post]
29 Jul 2010, 6:48 pm
" Amgen Inc. v. [read post]
